Results 101 to 110 of about 213,311 (303)
Financial Toxicity Associated with Biological Medicines: A Scoping Review
Clinical Pharmacology &Therapeutics, EarlyView.Financial toxicity, defined as the economic burden experienced by patients due to medication and other healthcare costs and their consequences, such as material, psychosocial and behavioral effects, represents a significant concern for individuals receiving biological medicines.
Laura Sara Maria Saarukka +4 more
wiley +1 more source
BMC Health Services Research, 2018 Background While many new medications may offer advantages over existing drugs, some newer drugs are reformulations of existing products that provide little innovation or incremental benefit while driving up drug costs.
Manvi Sharma +4 more
doaj +1 more source
The Association Between Opioid-Related Industry Payments and Opioid Prescribing at the Individual and Ecological Level in Pennsylvania [PDF]
, 2018 Objective: to understand how industry payments related to opioid products are associated with opioid prescribing in Pennsylvania. Methods: we merged the Open Payments data, Medicare Part D public use file, and Dartmouth Hospital Atlas of Health Care ...
George, PhD, MS, Brandon +2 more
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Biologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public ...
Chin Hang Yiu +4 more
wiley +1 more source
Income-Relating Medicare Part B and Part D Premiums Under Current Law and Recent Proposals: What Are the Implications for Beneficiaries? [PDF]
, 2012 Outlines differentiations in Medicare Parts B and D premiums by income level under current law, proposals to raise premiums for all beneficiaries or only for those with higher incomes, and potential implications for beneficiaries through ...
core
International Journal of Eating Disorders, EarlyView.ABSTRACT Objective Around one to two in five patients prematurely disengage from eating disorder therapy. This Forum paper suggests innovative strategies to increase retention and strategies for evaluating these with patients who have eating disorders.
Tracey D. Wade, Ulrike Schmidt
wiley +1 more source
Medication therapy management and adherence among US renal transplant recipients
Patient Preference and Adherence, 2016 Marie A Chisholm-Burns,1 Christina A Spivey,1 Elizabeth A Tolley,2 Erin K Kaplan2 1Department of Clinical Pharmacy, University of Tennessee College of Pharmacy, 2Department of Preventive Medicine, University of Tennessee College of Medicine, Memphis, TN,
Chisholm-Burns MA +3 more
doaj
Mind the Gap! Consumer Perceptions and Choices of Medicare Part D Prescription Drug Plans [PDF]
Medicare Part D provides prescription drug coverage through Medicare approved plans offered by private insurance companies and HMOs. In this paper, we study the role of current prescription drug use and health risks, related expectations, and subjective ...
Daniel McFadden +2 more
core
Forecasting heart failure: Seasonal alignment of heart failure outcomes in New York
ESC Heart Failure, Volume 12, Issue 2, Page 819-831, April 2025.Abstract Background Seasonal variations have been observed in heart failure (HF) hospitalization. Numerous explanatory mechanisms have been proposed, but no prior studies have examined potential contributors directly. Our objective was to identify specific factors that could contribute to seasonal variability using a large longitudinal dataset of HF ...
Prerna Gupta +5 more
wiley +1 more source
Celebrating Pork: The Dubious Success of the Medicare Drug Benefit [PDF]
, 2007 Projected costs for Medicare Part D have been revised downward, causing some analysts to claim that the program has proven itself a success. This report explores the factors behind the lower cost projections and reaches far different conclusions.
Dean Baker
core